Q3 2020 Sales Performance

Vaccines: revenue breakdown 2019 Revenues of £7.2bn (+19% CER) Products Synflorix (+11%) Other Rotarix (+6%) £0.5bn £0.6bn (7%) (8%) £0.5bn (7%) Meningitis (+15%) Hepatitis (+6%) £1.1bn £0.9bn (15%) (12%) Regions gsk Europe (-4%) £1.5bn (21%) £3.9bn £0.5bn (8%) Influenza (+1%) US (+39%) (55%) £1.8bn (25%) £0.6bn (8%) Boostrix (+11%) £0.7bn (10%) Infanrix/Pediarix (+6%) £1.8bn (25%) Shingrix (>100%) Source: GSK Full year 2019 results release - February 2020 All growths at constant exchange rates (CER). Breakdown percentages are approximate International (+9%) 65

View entire presentation